Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
clinicaltrials.gov Identifier: NCT01763866.
Publications
2 shownEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in ...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 1,951
- Institution
- Amgen (United States)
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.